# Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1

> **NCT04201431** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 24 (actual)

## Conditions studied

- Malaria, Vivax

## Interventions

- **BIOLOGICAL:** PvDBPII/Matrix-M1

## Key facts

- **NCT ID:** NCT04201431
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-24
- **Primary completion:** 2022-07-14
- **Final completion:** 2022-07-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201431, "Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04201431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*